Meeting Program
September 11-13, 2008
Harborplace Renaissance Hotel,
5th Floor Ballroom
Wednesday, September 10, 2008
6:00 p.m. – 8:30 p.m.Registration Desk Open
Thursday, September 11, 2008
7:00 a.m. – 7:00 p.m.
Registration Desk Open
8:30 a.m. – 9:00 a.m.
Welcome Remarks by Robert C. Gallo
and E. Albert Reece
HIV Entry
Co-Chairs:
- Edward A. Berger, National Institute of Allergy and Infectious Diseases, Bethesda, MD
- John P. Moore, Weill Cornell Medical College, New York, NY
Times and Speakers:
9:00 a.m. – 9:20 a.m.
Sriram Subramaniam, National Cancer Institute, Bethesda, MD
3-D Structure of Native HIV-1 gp120 Trimers and Mechanisms of Cellular Entry
9:20 a.m. – 9:40 a.m.
Carole Bewley, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
Structural Aspects of HIV-1 Entry, the Role of CCR5
9:40 a.m. – 10:00 a.m.
Gregory B. Melikian, Institute of Human Virology, University of Maryland School of Medicine
Visualization of HIV-1 Entry Pathways in Cells
10:00 a.m. – 10:20 a.m.
Athe Tsibris, Massachusetts General Hospital, Boston, MA
Tracking Dynamic HIV-1 Escape from CCR5 Antagonist Therapy in vivo by Deep Sequencing
10:20 a.m. – 10:40 a.m.
BREAK
10:40 a.m. - 11:00 a.m.
Kleio Anastasopoulou, Weill Cornell Medical College, New York, NY
A V3-Independent Pathway to Resistance to Small Molecule CCR5 Inhibitors
11:00 a.m. - 11:20 a.m.
Laurel Lagenaur, National Institute of Allergy and Infectious Diseases, Bethesda, MD
sCD4-17b, an Engineered Bifunctional HIV-1 Neutralizing Protein: Potent Cross Clade Activity and Potential Microbicide Use
HIV Infection Early Events
Co-Chairs:
- Ron Veazey, Tulane University, New Orleans, LA
- George Shaw, University of Alabama at Birmingham School of Medicine, Birmingham, AL
Times and Speakers:
11:20 a.m. – 11:40 a.m.Ronald Veazey, Tulane University
Early Events in Vaginal HIV Transmission
11:40 a.m. – 12:00 p.m.
Cynthia Derdeyn, Emory University Vaccine Center, Atlanta, GA
Escape from Neutralizing Antibody in Early Subtype C HIV-1 Infection
12:00 p.m. – 12:20 p.m.
George Shaw, University of Alabama at Birmingham School of Medicine
Identification of Full-Length Transmitted HIV-1 Genomes Reveals Extraordinary Dynamics and Precise Molecular Pathways of Early Virus Diversification, Adaptation and Immune Evasion
12:20 p.m. –12:40 p.m.
Robert Swanstrom, Center for AIDS Research, University of North Carolina Lineberger
Cancer Center
Complexity of the Transmitted Virus and Compartmentalization In Its Seminal Source
12:40 p.m. – 1:00 p.m.
Justin Hanes, Johns Hopkins University, Baltimore, MD
HIV Permeation Efficiency in Human Cervicovaginal Mucus
1:00 p.m. – 2:30 p.m.
LUNCH
Special Lectures
2:30 p.m. – 3:00 p.m.
Robert Siliciano, Johns Hopkins University, Baltimore, MD
HIV Persistence in Patients on HAART: Re-evaluating Prospects for Eradication
3:00 p.m. – 3:30 p.m.
Roger Pomerantz, Tibotec, Inc., Yardley, PA
New Viral and Tuberculosis Therapeutics for the 21st Century
Selected Abstracts
Co-Chairs:
- David Pauza, Institute of Human Virology, University of Maryland School of Medicine
- Marie-Lisa Gougeon, Institut Pasteur, Paris, France
Times and Speakers:
3:30 p.m. – 3:40 p.m.
Reinhardt Kurth, Robert Koch-Institute, Berlin, Germany
Reconstruction and Characterization of a Human Retrovirus with the Original Sequence at the Time of Integration
3:40 p.m. – 3:50 p.m.
Alfredo Garzino-Demo, Institute of Human Virology, University of Maryland School of Medicine
hBD2 Inhibits HIV Via CCR6, a Receptor Expressed on Memory, Dendritic and Th17 Cells
3:50 p.m. – 4:00 p.m.
Andrea Lisco, National Institute of Child Health and Human Development, Bethesda, MD
The Anti-Herpetic Drug Acyclovir Supresses HIV-1 in Herpes Virus-Infected Human Tissues After Conversion Into a Nucleoside Reverse Transcriptase Inhibitor
4:00 p.m. – 4:10 p.m.
Marie-Lise Gougeon, Institute Pasteur, Paris, France
NK Cells Contribute to the Constitution of HIV Reservoirs in Dendritic Cells, Involvement of HMGB-1
4:10 p.m. – 4:20 p.m.
Janet Douglas, Oregon Health and Science University
HIV Vpu Complexes with βTrCP to Direct the Degradation of the Virus Release Inhibitor BST-2 (Tetherin)
4:20 p.m. - 4:30 p.m.
Lili Gu, Centre for Research in Infectious Diseases, Dublin, Ireland
Molecular Studies of HIV-1 Rev Function
4:30 p.m. - 4:40 p.m.
BREAK
4:40 p.m. - 4:50 p.m.
Vineet KewalRamani, National Cancer Institute, Frederick, MD
CA-Dependent HIV-1 Nuclear Import Relies on Transportin-SR2
4:50 p.m. - 5:00 p.m.
Karin Moellling, University of Zurich, Switzerland
Self-Inactivation of HIV by its own RT/Rnase H
5:00 p.m. - 5:10 p.m.
Gaia Vasiliver-Shamis, New York University School of Medicine
HIV-1 Envelope gp120 Indicues a Stop Signal and Virological Synapse Formation in Non-infected CD4+ T Cells
5:10 p.m. - 5:20 p.m.
Makoto Yamagishi, University of Tokyo Institute of Medical Science
Promoter-Targeted shRNA Driven by Retroviral Vector Achieves Long-term Repression of HIV-1 Replication
5:20 p.m. - 5:30 p.m.
John Eldridge, Profectus Biosciences, Inc.
Plasmid DNA- and Live Viral Vector-Based Vaccine Approaches for the Treatment and Prevention of HIV Infection
Progression/Anti-Progression Factors
Co-Chairs:
- Daniel Douek, National Institute of Allergy and Infectious Diseases, Bethesda, MD
- Stephen O’Brien, National Cancer Institute, Frederick, MD
Times and Speakers:
5:30 p.m. – 5:50 p.m.
Daniel Douek, National Institute of Allergy and Infectious Diseases, Bethesda, MD
Differential CD4 T cell subset depletion at mucosal sites in HIV infection
5:50 p.m. – 6:10 p.m.
Stephen O’Brien, National Cancer Institute, Frederick, MD
Human Genes that Limit AIDS: An Update
6:10 p.m. – 6:30 p.m.
Galit Alter, Massachusetts General Hospital, Boston, MA
NK cells: Good Guys or Bad Guys?
6:30 p.m. – 6:50 p.m.
Xiaojiang Gao, National Cancer Institute, Frederick, MD
Immunogenetic Polymorphisms and Their Effects on AIDS Progression
6:50 p.m. – 7:10 p.m.
David B. Goldstein, Duke Institute for Genome Sciences and Policy
Host genetic determinants of response to HIV-1: A genome-wide perspective
Evening Poster Session and Welcome Reception
Co-Chairs:
- C. David Pauza, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD
- Roberta Kamin-Lewis, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD
- Arsene Burny, Robert Koch Institute, Berlin, Germany
7:10 p.m.
Welcome Reception
7:30 p.m.
Bassan Badram, University of Brussels, Belgium
HTLV-1 Infection of WE17/10 CD4+ Cell Line Leads to Progressive Alteration of Ca2+ Influx that Eventually Results in Loss of CD7 Expression and Activation of an Antiapoptopic Pathway Involving AKT and BAD Which Paves the Way for Malignant Transformation
7:37 p.m.
Weizao Chen, National Cancer Institute, Frederick, MD
Human Domain Antibodies Against HIV-1 as Exceptionally Potent Cross-Reactive Neutralizers
7:44 p.m.
Rafael Contreras-Galindo, University of Michigan Medical Center, Ann Arbor, Michigan
Human Endogenous Retrovirus-K (HML-2) in the Plasma of People with Lymphoma and Breast Cancer
7:51 p.m.
Sarah Daniels, National Institutes of Health, Bethesda, MD
Inhibition of HIV-1 Release by Cell Permeable Peptide
7:58 p.m.
Joachim Denner, Robert Koch Institute, Berlin, Germany
The gp41-Derived Immunosuppressive (isu) Peptide of HIV-1 Modulates Cytokine Release and Gene Expression in Human Immune Cells
8:05 p.m.
William Hearl, Immunomic Therapeutics, Inc., Gaithersburg, MD
Argotom-VAX: A Proposed Investigational HIV DNA Vaccine Composed of Selected Sequences of Clade B Gag, Pol, Nef, Tat, Vif, and Env Linked to Lysosomal Membrane Associated Protein (LAMP)
8:12 p.m.
Ramona Jochmann, University of Erlangen, Germany
O-linked N-Acetylglucosaminylation Represses HIV-1 Replication and Sp-1 Mediated Trans-Activation of the HIV-1 LTR
8:19 p.m.
Kyeongeun Lee, National Cancer Institute, Frederick, MD
Cell-cycle Dependent HIV-1 Killing is Mediated Through the Viral Protease
8:26 p.m.
Guan-Han Li, Johns Hopkins University School of Medicine, Baltimore, MD
Dramatic Enhancement of Uptake and Trafficking of HIV-1 Tat Protein via Modulation of Endocytosis Pathways
8:33 p.m.
Joseph Mattapallil, Uniformed Services University of the Health Sciences, Bethesda, MD
Increased IL-15 Production isAssociated with Higher Infection of Memory CD4 T Cells During Acute SIV Infection
8:40 p.m.
Andrea Matucci, University of Verona, Italy
Presence and Role of HLA-C in HIV-1 Infection
8:47 p.m.
Olanrewaju Onigbogi, University College Hospital, Ibadan, Nigeria
Prevalence of Human Papillomavirus (HPV) Infection Among HIV-Positive Women in the Pre-HAART and HAART Era in a Nigeria Clinic
8:54 p.m.
Clayton Onyango, MRC - Fajara Laboratories, Banjul, Gambia
HIV-2 Capsids Distinguishing High and Low Virus Load Patients in a West African Community Cohort
9:01 p.m.
Gilbert Siame, Zambia Rural Healthcare Outreach Services, Zambia
A Retrospective Study of HIV-Exposed Infacts/Children in Kitwe, Zambia
9:08 p.m.
Lydia Temoshok, Institute of Human Virology, Baltimore, MD
Type C Coping and Alexithymia are Associated Differentially with Specific Immune Mechanisms (Interleukin-6 and Beta-Chemokine Production) Linked to HIV Progression
9:15 p.m.
Nicole Yates, Duke University Medical Center, Durham, NC
HIV Frequently Elicits Mucosl and Plasma Env-Specific IgA with a Rapid Initial Decline in Acute Infection
9:22 p.m.
Donato Zipeto, University of Verona, Italy
Broad Spectrum Neutralizing Antibodies Against HIV-1 Elicited by Immunizing with Fusion Complexes
Friday, September 12, 2008
8:00 a.m. – 5:30 p.m.
Registration Desk Open
Special Lectures
9:00 a.m. – 9:30 a.m.
Guiliano Elia, University College Dublin, Ireland
In vivo and ex-vivo proteomics for target discovery in cancer
9:30 a.m. – 10:00 a.m.
Ronald C. Desrosiers, Harvard University, Cambridge, MA
V1-V2 is the Principal Determinant of the Strain Specificity of the Neutralizing Antibody Response AND Carbohydrates on gp41 Shield Epitopes That Can Be the Targets of Neutralizing Antibodies
10:00 a.m. – 10:30 a.m.
Anthony Fauci, National Institute of Allergy and Infectious Diseases, Bethesda, MD
α4β7: A Newly Discovered Receptor for HIV
10:30 a.m. – 10:45 a.m.
BREAK
10:45 a.m. – 11:15 a.m.
Michael Houghton, Epiphany Biosciences, San Francisco, CA
Hepatitis C and Cancer
11:15 a.m. – 11:45 a.m.
Hilary Koprowski, Thomas Jefferson University, Philadelphia, PA
Maurice Hillman Memorial Lecture
11:45 a.m. - 12:15 p.m.
George Klein, Karolinska Institutet, Stockholm, Sweden -
In Honor of Lifetime Achievement - Awardee Isaac Witz
HIV Malignancies
Co-Chairs:
- Guy de Thé, Institut Pasteur, Paris, France
- Robert Yarchoan, National Cancer Institute, Bethesda, MD
Times and Speakers:
12:15 p.m. – 12:35 p.m.Eva Klein, M.D., Karolinska Institute, Stockholm, Sweden
The Role of the Environment in EBV-Associated Lymphoid Malignancies
12:35 p.m. – 12:55 p.m.
Eric Engels, National Cancer Institute, Bethesda, MD
HIV and Cancer: Current Trends and Insights
12:55 p.m. – 1:15 p.m.
Don Ganem, University of California San Francisco
MicroRNAs and the Biology of KSHV Infection
1:15 p.m. – 1:35 p.m.
Antonino Carbone, Istituto Nazionale Tumori, Milano, Italy
HIV-Associated Lymphomas. Focus on Unusual Lymphomas Occurring Specifically in HIV-Infected Patients
1:35 p.m. – 2:50 p.m.
LUNCH
Controlling Replication of Human Retroviruses
Co-Chairs:
- Roberto Accola, Ph.D., University of Insubria, Varese, Italy
- Warner Greene, Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, CA
- Guido Poli, San Raffaele Scientific Institute, Milano, Italy
Times and Speakers:
2:50 p.m. – 3:10 p.m.
Roberto Accola, Ph.D., University of Insubria, Varese, Italy
Insight Into the Molecular Mechanisms of CIITA-Mediated Inhibition of HIV-1 and HTLV Replication
3:10 p.m. – 3:30 p.m.
Warner Greene, Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, CA
Apobec3: A Modern Twist to A Classic Retroviral Mystery
3:30 p.m. – 3:50 p.m.
Paul Bienasz, Aaron Diamond AIDS Research Center, New York, NY
Tetherin, An Interferon-alpha Induced Inhibitor of Retrovirus Release that is Antagonized by Vpu
3:50 p.m. – 4:10 p.m.
Victor Garcia-Martinez, Southwestern Medical School, Dallas, TX
Humanized Mouse Models for the In-Vivo Analysis of HIV Infection
4:10 p.m. – 4:30 p.m.
Carlos de Noronha, Albany Medical College, Albany, NY
Vpr as a Mediator of Proteasomal Degradation and Other Functions
4:30 p.m. – 4:50 p.m.
Judy Lieberman, Immune Disease Institute, Harvard Medical College, Cambridge, MA
The SET complex acts as a barrier to autointegration of HIV-1
4:50 p.m. – 5:10 p.m.
Abraham Brass, Massachusetts General Hospital, Boston, MA
Finding Host Proteins Required for HIV Replication
Selected Abstracts
5:10 p.m. – 5:20 p.m.
Guido Poli, San Raffaele Scientific Institute, Milano, Italy
Polarization of M1 and M2 macrophages and HIV infection
5:20 p.m. – 5:30 p.m.
Jonathan Gershoni, Tel Aviv University, Israel
Peptide Stabilization of gp120 Confirmation: a Novel Israel Vaccine Candidate
Gala Reception and Dinner
7:00 p.m.
- Lifetime Achievement Award for Scientific Contributions: Isaac P. Witz, Tel Aviv University
- Lifetime Achievement Awards for Public Service: John D. Evans and Robert K. Gray
- Guest Speaker: William Haseltine, Haseltine Associates, Ltd.
Saturday, September 13, 2008
7:30 a.m. – 5:00 p.m.
Registration Desk Open
Clinical HIV Session
Co-Chairs:
- Alain Lafeuillade, General Hospital, Toulon, France
- Robert R. Redfield, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD
- Mark Wainberg, McGill AIDS Centre, Jewish General Hospital, Montreal, Canada
Times and Speakers:
8:30 a.m. – 8:50 a.m.Mark Wainberg, McGill AIDS Centre, Jewish General Hospital, Montreal, Canada
Transmission Networks of Drug Resistance Acquired in Primary/Early Stage HIV Infection
8:50 a.m. – 9:10 a.m.
John Bartlett, Johns Hopkins University, Baltimore, MD
HIV Persistence in Patients on HAART: Re-evaluating Prospects for Eradication
9:10 a.m. – 9:30 a.m.
Charles F. Farthing, Merck, Whitehouse Station, NJ
An Update on Raltegravir (Isentress)
9:30 a.m. – 9:50 a.m.
Randall Tressler, Pfizer, New York, NY
Evaluation of Efficacy and Immune Recovery of Optimized Background Therapy (OBT) Plus Maraviroc (MVC) vs Placebo (PBO) in Treatment Experienced (TE) Patients with Only R5 HIV-1, Combined Analysis of MOTIVATE 1 and 2
9:50 a.m. – 10:10 a.m.
Anthony Amoroso, Institute of Human Virology, University of Maryland School of Medicine
HIV Therapeutics in Resource Limited Settings – Status and Future Directions
10:10 a.m. – 10:30 a.m.
Tomas Cihlar, Gilead Sciences, Foster City, CA
Update on Gilead Sciences Anti-HIV Development Programs
10:30 a.m. – 10:40 a.m.
Olga Latinovic, Institute of Human Virology, Baltimore, MD
Rapamycin Enhances the Anti-HIV Activity of CCR5 Antagonist Vicriviroc
10:40 a.m. – 11:05 a.m.
BREAK
Preventative Vaccines
Co-Chairs:
- George Pavlakis, National Cancer Institute, Frederick, MD
- George Lewis, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD
- Reinhardt Kurth, Robert Koch-Institute, Berlin, Germany
Times and Speakers:
11:05 a.m. – 11:25 a.m.
Garnett Kelsoe, Department of Immunology, Duke University
Why Do So Few Antibodies Neutralize HIV-1? Tests of the "Tolerance Hypothesis"
11:25 a.m. – 11:45 p.m.
George Pavlakis, National Cancer Institute, Bethesda, MD
Getting the Right Immune Response to HIV: Evaluation of Protective Immune Responses After Vaccination of Rhesus Macaques
11:45 p.m. – 12:05 p.m.
Susan Zolla-Pazner, New York University Medical Center, New York, NY
Induction of Cross-clade Neutralizing Antibodies in Rabbits Using a DNA Prime/Protein Boost Immunization Regimen
12:05 p.m. – 12:25 p.m.
Louis T. Picker, Oregon Health and Science University, Portland, OR
Prospects for an AIDS Vaccine: Can Effector-Memory T Cell Responses Contribute?
12:25 p.m. – 12:45 p.m.
Wuyuan Lu, Institute of Human Virology, University of Maryland School of Medicine
Human Defensins - Small in Size, but Big in Functionality
12:25 p.m. – 1:30 p.m.
LUNCH
Therapeutic Vaccines Against Cancer and HIV
Co-Chairs:
- Jay Berzofsky, National Cancer Institute, Bethesda, MD
- William A. Blattner, Institute of Human Virology, University of Maryland School of Medicine
- Angus Dalgleish, St. George’s University of London
Times and Speakers:
1:30 p.m. – 1:50 p.m.Angus Dalgleish, St. George’s University of London, London, England
The C5 Region of gp120; a Therapeutic Vaccine Target?
1:50 p.m. – 2:10 p.m.
Jay Berzofsky, National Cancer Institute, Bethesda, MD
Mechanisms by which Synergistic Combinations of TLR Ligands Enhance T-Cell Responses to Vaccines
2:10 p.m. – 2:30 p.m.
Jeffrey Schlom, National Cancer Institute, Bethesda, MD
Vector-based Vaccines for Cancer Therapy
2:30 p.m. – 2:50 p.m.
Elizabeth Jaffee, Johns Hopkins University, Baltimore, MD
Recruitment of High Avidity Antigen-Specific T Cells in Pancreatic Cancer Patients
More on Preventative Vaccines
Co-Chairs:
- Robert C. Gallo, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD
- José Esparza, Bill and Melinda Gates Foundation, Seattle, WA
Times and Speakers:
2:50 p.m. – 3:10 p.m.Nelson Michael, United States Military HIV Research Program, Rockville, MD
Development of Preventive HIV Vaccines in the US Military HIV Research Program
3:10 p.m. – 3:30 p.m.
Gary Nabel, Vaccine Research Center, National Institutes of Health, Bethesda, MD
Rational Vaccine Design and the Development of an AIDS Vaccine
3:30 p.m. – 3:50 p.m.
Glenda Gray, Perinatal HIV Research Unit, University of the Witwatersrand, South Africa
Continuing Clinical Trials for HIV Vaccine Research
3:50 p.m. – 4:10 p.m.
Gunnel Biberfeld, Karolinska Institutet, Stockholm, Sweden
HIV-specific Immune Responses in Healthy Volunteers Immunized with a Multigene, Multiclade HIV-1 DNA vaccine and Boosted with HIV-1 MVA in Sweden and Tanzania
4:10 p.m. – 4:30 p.m.
Philip Johnson, Children’s Hospital of Philadelphia, Philadelphia, PA
A Novel Model for In Vivo SIV Neutralization
Selected Abstracts
4:30 p.m. – 4:45 p.m.
Luigi Buonaguro, Istituto Nazionale Tumori "Fond. G. Pascale," Naples, Italy
Morphogenomic Immune Responsiveness to Preventive/Therapeutic Vaccines
4:40 p.m. - 4:50 p.m.
Antony Dimitrov, Profectus Biosciences, Inc.
Development of the Broadly Neutralizing Human Antibody m9 for Anti-HIV Prophylactics
Closing Remarks
4:50 p.m.
By Robert C. Gallo